| Rachael Christine Parker, DO | |
|
1801 Hickman Rd, Des Moines, IA 50314-1505 | |
| (515) 282-5640 | |
| (515) 282-2332 |
| Full Name | Rachael Christine Parker |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 1801 Hickman Rd, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356788129 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 04071 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Broadlawns Medical Center | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Broadlawns Medical Center | 3678466166 | 207 |
News Archive
SFU health sciences researcher Stefanie Rezansoff has published a new study on the treatment of serious mental illnesses among people who are homeless. This is the first study to investigate adherence to antipsychotic medication in this population.
More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.
Could number two be number one when it comes to combating recurrent Clostridium difficile (CDI) infections?Using genetic material analysis and machine learning, UBC researchers have pinpointed several key factors to ensure successful fecal microbiota transplants (FMT), which have proven successful in treating bacterial infections in the gut including illnesses like C. difficile, Crohn's Disease, Colitis and even obesity, explains lead author Negin Kazemian.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
› Verified 5 days ago
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
SFU health sciences researcher Stefanie Rezansoff has published a new study on the treatment of serious mental illnesses among people who are homeless. This is the first study to investigate adherence to antipsychotic medication in this population.
More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.
Could number two be number one when it comes to combating recurrent Clostridium difficile (CDI) infections?Using genetic material analysis and machine learning, UBC researchers have pinpointed several key factors to ensure successful fecal microbiota transplants (FMT), which have proven successful in treating bacterial infections in the gut including illnesses like C. difficile, Crohn's Disease, Colitis and even obesity, explains lead author Negin Kazemian.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachael Christine Parker, DO 1801 Hickman Rd, Des Moines, IA 50314-1505 Ph: (515) 282-5640 | Rachael Christine Parker, DO 1801 Hickman Rd, Des Moines, IA 50314-1505 Ph: (515) 282-5640 |
News Archive
SFU health sciences researcher Stefanie Rezansoff has published a new study on the treatment of serious mental illnesses among people who are homeless. This is the first study to investigate adherence to antipsychotic medication in this population.
More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.
Could number two be number one when it comes to combating recurrent Clostridium difficile (CDI) infections?Using genetic material analysis and machine learning, UBC researchers have pinpointed several key factors to ensure successful fecal microbiota transplants (FMT), which have proven successful in treating bacterial infections in the gut including illnesses like C. difficile, Crohn's Disease, Colitis and even obesity, explains lead author Negin Kazemian.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has won two significant patent re-examination cases brought by Isis Pharmaceuticals.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
› Verified 5 days ago
Neetha Molakala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 University Ave, Suite 120, Des Moines, IA 50314 Phone: 515-248-1500 Fax: 515-248-1510 | |
Matthew Helmick Williams, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1801 Hickman Rd, Des Moines, IA 50314 Phone: 515-282-5640 Fax: 515-282-2332 | |
Todd Eberle, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-8678 Fax: 515-643-5802 | |
Evan Douglas Peterson, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6520 Se 14th St, Des Moines, IA 50320 Phone: 515-953-1500 Fax: 515-953-2136 | |
April Winters, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2353 Se 14th St, Des Moines, IA 50320 Phone: 515-248-1400 Fax: 515-248-1414 | |
Kelli A Roenfanz, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 840 East University Avenue, Des Moines, IA 50316 Phone: 515-265-4211 Fax: 515-309-5993 | |
Dr. Sarah Sweeney Gude, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3509 E 29th St, Des Moines, IA 50317 Phone: 515-248-1600 Fax: 515-248-1610 |